<DOC>
	<DOCNO>NCT00031720</DOCNO>
	<brief_summary>RATIONALE : Soy protein supplement may effective reduce hot flush postmenopausal woman receive tamoxifen breast disease . PURPOSE : Randomized phase II trial determine effectiveness soy protein supplement reduce hot flush postmenopausal woman receive tamoxifen breast disease ductal hyperplasia breast cancer .</brief_summary>
	<brief_title>Soy Protein Supplement In Treating Hot Flashes Postmenopausal Women Receiving Tamoxifen Breast Disease</brief_title>
	<detailed_description>OUTLINE : This randomize , double-blind , placebo-controlled , multicenter study . Patients stratify accord duration hot flash ( less 9 month vs 9 month ) frequency hot flash ( 7 9 per day vs 9 per day ) . For information regard treatment regimen , please see treatment arm section . Primary objective : 1 . To compare effect daily soy supplementation versus placebo daily number hot flush experience postmenopausal woman take tamoxifen measure three month baseline 2 . To compare effect daily soy supplementation versus placebo hot flush severity measure average daily hot flash score population woman measure three month baseline Secondary objective : 1 . To evaluate effect soy supplementation compare woman randomize placebo quality life measure Medical Outcomes Study ( MOS ) sleep subscale , Mental Health Inventory ( MHI ) , CES-D Short Form , Menopause Reproductive Health Questionnaire , General Quality Life Form 2 . To measure effect soy supplementation compare woman randomize placebo serum isoflavones , estradiol , SHBG , IGF1 IGFBP3 level measure hormonal change 3 . To estimate effect daily soy supplementation versus placebo time first relief hot flush A total 112 patient accrue study . Patients follow 6 month post-randomization .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hot Flashes</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Eligibility Criteria : 1 . Histologic documentation atypical ductal hyperplasia , ductal carcinoma situ ( DCIS ) , lobular carcinoma situ ( LCIS ) , invasive adenocarcinoma breast stage IIII A . 2 . Current daily tamoxifen use . Any planned surgery , adjuvant chemotherapy radiation must complete . 3 . History bothersome hot flush : ≥ 7 hot flushes/day , sufficiently severe intervention desire . Participants must bothersome hot flush least one month prior enrollment . 4 . Postmenopausal status : surgical menopause , menses ≥ 1 year postmenopausal FSH level . 5 . No concurrent use vitamin E , progestins ( Megace® others ) , clonidine , belladonna derivative commercially available soy supplement preparation treatment hot flush . Participants must least 4week washout period prior day 1 runin use . Participants may take low dos vitamin E part multivitamin . 6 . Concurrent use antidepressant , Paxil® , Prozac® , Effexor® allow participant stable dose month purpose medication control hot flush . If SSRI 's use hot flash , must discontinue 4 week prior day 1 runin . 7 . No concurrent systemic hormone replacement therapy use vaginal estrogen cream . Use estradiol release vaginal ring ( Estring® ) allow . 8 . No history soy milk intolerance 9 . CALGB performance status 02</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>lobular breast carcinoma situ</keyword>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
	<keyword>ductal breast carcinoma situ</keyword>
	<keyword>hot flash</keyword>
</DOC>